Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Enterprise Value (2018 - 2025)

X4 Pharmaceuticals' Enterprise Value history spans 8 years, with the latest figure at -$217.0 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 289.68% year-over-year to -$217.0 million; the TTM value through Dec 2025 reached -$217.0 million, down 289.68%, while the annual FY2025 figure was -$217.0 million, 289.68% down from the prior year.
  • Enterprise Value reached -$217.0 million in Q4 2025 per XFOR's latest filing, down from -$69.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$39.2 million in Q2 2025 to a low of -$217.0 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$93.6 million, with a median of -$87.6 million recorded in 2021.
  • The largest YoY upside for Enterprise Value was 73.36% in 2025 against a maximum downside of 289.68% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$81.8 million in 2021, then crashed by 48.82% to -$121.7 million in 2022, then increased by 18.49% to -$99.2 million in 2023, then surged by 43.86% to -$55.7 million in 2024, then tumbled by 289.68% to -$217.0 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Enterprise Value are -$217.0 million (Q4 2025), -$69.6 million (Q3 2025), and -$39.2 million (Q2 2025).